AbbVie has submitted its Hepatitis C treatment to the European regulator, a triple-pronged therapy set to rival to Gilead's Sovaldi. Gilead's hit the US market last year, and is already ...

Less than three years after Sovaldi’s launch, hepatitis C (hep C) treatment has been transformed, thanks to the drug and rapidly-evolving competition in the field. But only a small percentage of ...

Additionally, the company has progressed its herpes treatment, ABI-1179, into the Phase 1b portion of its ongoing study after positive interim results from the Phase 1a trial. Meanwhile, H.C ...

The Phase 1a ... C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. “We believe STAR-0310 will be the best-in-class therapy due to efficacy, safety and tolerability, and treatment ...